Vantage Health USA

Vantage Health USA helps adults transform their health with provider-prescribed peptide and hormone therapy paired with dedicated 1-on-1 coaching — legitimate, U.S.-sourced, and delivered to the door.

The U.S. peptide therapeutics market was estimated at $21.24 billion in 2025, sitting inside a global peptide market worth nearly $50 billion — fueled by surging demand for GLP-1s, hormone optimization, and longevity-focused care.

The global peptide therapeutics market is projected to grow from $49.7 billion in 2025 to $100 billion by 2034, at an 8.1% CAGR. The U.S. alone is expected to reach nearly $35 billion by 2035, driven by metabolic disease, obesity, hormone therapy, and mainstream adoption of longevity protocols.

Subscription-based, all-inclusive monthly pricing across 13+ programs in four pillars: Men's, Women's, Cognitive, and Recovery & Longevity. Tiers run from $497 to $1,997 per month with a 3-month minimum — producing predictable recurring revenue, strong retention, and expansion revenue as clients upgrade from Basic to Advanced to VIP. Every program bundles provider-prescribed therapy, labs, and coaching into one flat price, while competitors upsell each piece separately.

Our team was built out of frustration — tired of watching people get misled by self-proclaimed gurus pushing off-market, gray-area compounds with no clinical oversight and no accountability. We founded Vantage to change that. Every protocol is prescribed by a licensed U.S. provider through our clinical partner Impact Health Network, every compound is sourced from licensed U.S. compounding pharmacies, and every client gets a real human coach — not a chatbot and not a sales rep. Our mission is simple: bring legitimacy, transparency, and real results to a category that's been overrun by hype.